| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
| Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. |
|
| Chapter Links... |
 Haematology and Oncology Protocols and Guidelines |
| DSU: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? (March 2019) |
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
Atezolizumab infusion
|
 Restricted
|
Consultant Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017)
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018)
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018)
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019)
NICE TA638:Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (July 2020)
NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (July 2020)
|
Axitinib (Inlyta)
|
Restricted
|
Patients who require treatment of renal cell carcinoma should be referred to Leeds Teaching Hospital Trust
Axitinib is not stocked at Airedale NHS Foundation Trust
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015)
|
Brentuximab infusion (Adcetris)
|
Restricted
|
For treatment of CD30-positive cutaneous T-cell lymphoma in-line after at least one other therapy (second-line) with NICE TA577.
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017)
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017)
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018)
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019)
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (August 2020)
|
Crizotinib (Xalkori)
|
Restricted
|
- Crizotinib Capsules (Xalkori®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: Crizotinib - risk of cardiac failure (November 2015)
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018)
|
Daratumumab infusion ( Darzalex)
|
Restricted
|
- Daratumumab infusion (Darzalex®)
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus (August 2019)
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018)
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019)
|
Dasatinib (Sprycel)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
|
Durvalumab
|
Restricted
|
Supported for treatment of locally advanced non small-cell lung cancer after platinum-based chemo radiation in-line with NICE TA578.
Consultant oncologist use only.
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019)
|
Eribulin ( Halaven)
|
Restricted
|
- Eribulin Solution for Injection
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016)
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018)
|
Ibrutinib (Imbruvica)
|
Restricted
|
Consultant Haematologist use only
Ibrutinib is only available via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drugs Fund
Drug Safety Update:Ibrutinib: reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017)
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017)
NICE TA491: Ibrutinib for treating Waldenstroms macroglobulinaemia (November 2017)
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
|
Isatuximab infusion (Sarclisa)
|
Restricted
|
For the treatment of relapsed and refractory myeloma (with pomalidomide and dexamethasone) under MHRA Early Access to medicines Scheme.
Consultant Haematologist use only.
|
|
|
Neratinib (Nerlynx)
|
Restricted
|
- Niraparib tablets (Nerlynx®)
Approved as an option for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab in-line with provisional NICE recommendations.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
|
|
Niraparib (Zejula)
|
Restricted
|
- Niraparib Capsules (Zejula®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
Consultant Oncologist use only
|
TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018)
|
Nivolumab (Opdivo)
|
Restricted
|
Consultant Oncologist use only.
For use at Specialist Centres only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019)
MHRA Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017)
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017)
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017)
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017)
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018)
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019)
TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (May 2019)
|
Olaparib (Lynparza)
|
Formulary
|
- Olaparib capsules - For the treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer in-line with NICE TA381.
- Olaparib tablets - For maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in-line with NICE TA598.
Consultant Medical Oncologist use only
|
 DSU: Olaparib: Risk of medication errors with new pharmaceutical form (May 2018)
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (August 2019)
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (January 2020)
SSC2101 - Olaparib 2nd and 3rd line treatment of ovarian, fallopian tube or peritoneal cancer (December 2019)
|
Pembrolizumab (Keytruda)
|
Restricted
|
For use at specialist centres only in line with NICE TA357 and TA366.
For treating for treating PD-L1-positive non-small-cell lung cancer after chemotherapy in-line with NICE TA428 and NICE TA447.
For locally advanced or metastatic urothelial cancer after platinum-containing therapy in-line with NICE TA519
Consultant Medical Oncologist use only
Approved for Hodgkin lymphoma in-line with NICE TA540
Consultant haematologist use only
Approved for first-line treatment (in combination with pemetrexed and cisplatin chemotherapy) of metastatic, non-squamous non-small-cell lung cancer in patients with no EGFR or ALK-positive mutations with NICE TA557.
Consultant Oncologist use only
Approved for use (in combination with carboplatin and paclitaxel) as an option for untreated metastatic squamous NSCLC in-line with NICE TA600
Consultant Medical Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Drug Safety Update: Nivolumab, pembrolizumab: reports of organ transplant rejection (July 2017)
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017)
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018)
NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018)
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018)
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018)
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only]
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019)
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (September 2019)
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (September 2020)
NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
|
Pertuzumab (Perjeta)
|
Restricted
|
Pertuzumab is also available for some indications via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drug Fund
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019)
|
Ponatinib (Iclusig)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Drug Safety Update: Ponatinib (Iclusig): risk of vascular occlusive eventsupdated advice on possible dose reduction (April 2017)
DSU: Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome (October 2018)
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017)
|
Ribociclib (Kisqali)
|
Restricted
|
- Ribociclib tablets (Kisqali®)
Approved by D&TC as a treatment option (with fulvestrant) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in-line with NICE TA593
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
|
|
Rucaparib tablets (Rubraca)
|
Restricted
|
Consultant Oncologist use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (November 2019)
|
Venetoclax
|
Restricted
|
- Venetoclax film-coated tablets
Consultant Haemotologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017)
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019)
|
|
|
| 08.01.05 |
Amsacrine |
|
|
| 08.01.05 |
Arsenic trioxide |
|
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab (Avastin)
(Oncology)
|
Restricted
|
Bevacizumab is only available for via the CDF. For further information see the link below.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drug Fund: Bevacizumab
MHRA Drug Safety Update:Bevacizumab and sunitinib: risk of osteonecrosis of the jaw (January 2011)
NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend]
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend]
|
| 08.01.05 |
Bexarotene |
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib (Velcade)
|
Restricted
|
Bortezomib is also available for some indications via the CDF list. See link below for further information.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
Cancer Drugs Fund
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007)
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015)
|
Carfilzomib (Kyprolis)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
DSU: Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events (August 2019)
DSU: Carfilzomib (Kyprolis▼): risk of reactivation of hepatitis B virus (November 2019)
NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017)
|
Ixazomib (Ninralo)
|
Restricted
|
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab (Erbitux)
|
Restricted
|
Available via NHSE. See the link below for further information.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only)
NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED
NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017)
TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
|
| 08.01.05 |
Crisantaspase |
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine
|
Restricted
|
Dacarbazine Injection
Dacarbazine Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide
|
Restricted
|
Hydroxycarbamide Capsules
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Ipilimumab |
|
|
| 08.01.05 |
Mitotane |
|
|
| 08.01.05 |
Panitumumab |
|
|
Panitumumab infusion (Vectibix)
|
Restricted
|
- Panitumumab infusion (Vectibix®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
|
| 08.01.05 |
Pentostatin |
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin
|
Restricted
|
Carboplatin Injection
Carboplatin Infusion
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Cisplatin
|
Restricted
|
Cisplatin Infusion
Cisplatin Injection
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
Oxaliplatin
|
Restricted
|
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer (April 2006)
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)
|
| 08.01.05 |
Porfimer sodium and temoporfin |
|
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine
|
Restricted
|
Procarbazine Capsules
Restricted for use within agreed protocols under the supervision of appropriate specialists
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Abemaciclib tablets (Verzenios )
|
Restricted
|
- Abemaciclib tablets (Verzenios®)
Consultant Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
|
Afatinib (Giotrif)
|
Restricted
|
- Afatinib Tablets (Giotrif®)
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
|
Alectinib capsules (Alecensa)
|
Restricted
|
- Alectinib Capsules (Alecensa®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
|
Bosutinib (Bosulif)
|
Restricted
|
- Bosutinib Tablets
Consultant Haematologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation(May 2016)
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
|
Brigatinib tablets (Alunbrig)
|
Restricted
|
- Brigatinib tablets (Alunbrig®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
|
Ceritinib capsules (Zykadia)
|
Restricted
|
- Ceritinib Capsules (Zykadia®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
|
Dacomitinib (Vizimpro)
|
Restricted
|
Consultant Oncology use only
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (August 2019)
|
Erlotinib
|
Restricted
|
|
NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
|
Everolimus (Afinitor)
|
Restricted
|
- Everolimus Tablets (Afinitor®)
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
|
Gefitinib
|
Restricted
|
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
|
Idelalisib (Zydelig)
|
Restricted
|
|
EMA recommends new safety measures for Zydelig (March 2016)
MHRA Drug Safety Update: Idelalisib (Zydelig): updated indications and advice on minimising the risk of infection (September 2016)
NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
NICE TA604: Idelalisib for treating refractory follicular lymphoma (October 2019)
|
Imatinib
|
Restricted
|
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
|
Larotrectinib 20mg/mL oral solution (Vitrakvi)
|
Restricted
|
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours (May 2020)
|
Lorlatinib (Lorviqua)
|
Restricted
|
- Lorlatinib Tablets (Lorviqua®)
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (May 2020)
|
Nilotinib (Tasigna)
|
Restricted
|
- Nilotinib Tablets
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
MHRA Drug Safety Update: BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation (May 2016)
NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
|
Nintedanib capsules (Vargatef)
|
Restricted
|
- Nintedanib Capsules (Vargatef®)
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
|
Osimertinib mesylate ( Tagrisso)
|
Restricted
|
Consultant Medical Oncologist use only.
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
|
Palbociclib (Ibrance)
|
Restricted
|
- Palbociclib capsules
- Palbociclib capsules with fulvestrant injection
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (January 2020)
|
Ribociclib (Kiskali)
|
Restricted
|
- Ribociclib Tablets
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (August 2019)
|
Ruxolitinib (Jakavi)
|
Restricted
|
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel (Jevtana)
|
Restricted
|
- Cabazitaxel Concentrate for Infusion
Blueteq® registration and approval for use is required for this product before it may be dispensed.
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016)
|
Docetaxel
|
Restricted
|
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
|
Paclitaxel
|
Restricted
|
- Paclitaxel Injection
- Paclitaxel Infusion
- Paclitaxel as albumin-bound nanoparticles Infusion
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015)
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003)
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride
|
Restricted
|
|
DSU: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events (March 2019)
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017)
|
Topotecan
|
Restricted
|
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)
|
| 08.01.05 |
Trabectedin |
|
|
| 08.01.05 |
Trastuzumab |
|
|
Trastuzumab (Herceptin Ontruzant)
|
Restricted
|
- Trastuzumab Intravenous Injection (Herceptin®)
- Trastuzumab Subcutaneous Injection (Herceptin ®)
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)
NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)
|
Trastuzumab emtansine (Kadcyla)
|
Restricted
|
- Trastuzumab emtansine Powder for Concentrate for Solution for Infusion (Kadcyla®)
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017)
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (June 2020)
|
| 08.01.05 |
Tretinoin |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Green - Drugs suitable for generalised use in accordance with position summary.
Inform primary care of need to prescribe using a TTO chart if in patient or Treatment Advice Note (TAN) if Outpatient.
|
|
Amber - these drugs require specialist initiation or recommendation |
|
Amber Share Care - Drugs suitable for generalist use, in accordance with position summary, normally following specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red. |
|
Red - Drugs for specialist use only, in accordance with position summary. GPs should not be asked to prescribe these products. |
|
Red ULM - Unlicensed medicines for specialist use only, in accordance with position summary. GPs should not be asked to prescribe these products. |
|
Grey drugs - No formal commissioning position. Check appropriate CCG /NHSE commissioning list or contact CCG/NHSE Medicines Management team for advice. Fill in individual funding request for appropriate CCG/NHSE. This will need to be signed by the Chief Pharmacist and a copy of the relevant DTC submission attached. |
|
Black - Drugs not routinely commissioned so should not usually be prescribed |
|
|
|
